C3AR1, complement C3a receptor 1, 719

N. diseases: 73; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0004096
Disease: Asthma
Asthma
0.250 Biomarker disease BEFREE In silico functional characterization of the asthma-associated SNPs also supported the contribution of C3AR1 and additional genes including SYNE1, LINGO2, and IFNG-AS1. 27445529 2016
CUI: C0004096
Disease: Asthma
Asthma
0.250 Biomarker disease RGD Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in rat and murine models of lung inflammation. 17544263 2007
CUI: C0004096
Disease: Asthma
Asthma
0.250 GeneticVariation disease BEFREE Support for a causal role for altered anaphylatoxin production in human disease comes from reports of exaggerated complement production in the lungs of asthmatics as well as the association of asthma with polymorphisms in C3/C3aR genes. 16091207 2005
CUI: C0004096
Disease: Asthma
Asthma
0.250 AlteredExpression disease LHGDN Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma. 15039137 2004
CUI: C0004096
Disease: Asthma
Asthma
0.250 GeneticVariation disease BEFREE A patient-only association study suggested that severity of childhood BA was associated with 1526G/A of the C3AR1 gene (P = 0.0057). 15278436 2004
CUI: C0004096
Disease: Asthma
Asthma
0.250 AlteredExpression disease BEFREE These results demonstrate the expression of C3aR and C5aR by cells endogenous to the lung, and, given the participation of bronchial epithelial and smooth muscle cells in the pathology of diseases such as sepsis and asthma, the data suggest a role for these receptors during lung inflammation. 11160252 2001
CUI: C0024115
Disease: Lung diseases
Lung diseases
0.200 Biomarker group RGD Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in rat and murine models of lung inflammation. 17544263 2007
Respiratory Distress Syndrome, Adult
0.200 Therapeutic disease RGD Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. 16782534 2006
CUI: C0035126
Disease: Reperfusion Injury
Reperfusion Injury
0.200 Biomarker disease RGD Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. 15159277 2004
HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1
0.100 GeneticVariation disease CLINVAR
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.040 Biomarker group BEFREE We conclude that the C3aR antagonist, SB 290157, may be used in the future to limit the neuronal death by limiting secondary phagocytosis after stroke. 31814819 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.040 Biomarker group BEFREE Complement C3a receptor (C3aR) is a key mediator of post-ischemic cerebral injury, and pharmacological antagonism of the C3a receptor is neuroprotective in stroke. 31138990 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.040 Biomarker group BEFREE The development of tissue-specific C3aR knockout mice and more specific C3aR antagonists is warranted to facilitate our understanding of the role of the C3aR in brain ischemia with the ultimate goal of clinical translation of therapies targeting C3aR in stroke patients. 31102134 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.040 Biomarker group BEFREE The pathophysiological relevance of C3aR was scrutinized with the use of disease models of myocardial infarction and stroke. 29802205 2018
CUI: C0004364
Disease: Autoimmune Diseases
Autoimmune Diseases
0.030 Biomarker group BEFREE Thus, whilst the C3aR modulates some elements of disease pathogenesis, overall it is not critical in effector responses and glomerular injury caused by autoimmunity to MPO. 29315316 2018
CUI: C0004364
Disease: Autoimmune Diseases
Autoimmune Diseases
0.030 Biomarker group BEFREE Complement 3a receptor (C3aR) and complement 5a receptor (C5aR) have been reported to be involved in T cell mediated autoimmune disease. 29138505 2017
CUI: C0004364
Disease: Autoimmune Diseases
Autoimmune Diseases
0.030 Biomarker group BEFREE Complement activation products C3a and C5a have broad pro-inflammatory potential through their receptors, C3aR and C5aR, and contribute to the pathogenesis of several inflammatory and autoimmune diseases, but their roles in IgAN are poorly defined. 24327134 2014
CUI: C0028754
Disease: Obesity
Obesity
0.020 Biomarker disease BEFREE We conducted a structure-function relationship study on the neuropeptide TLQP-21, a promising target for obesity, and its complement 3a receptor (C3aR1). 31484069 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.020 GeneticVariation disease BEFREE Strikingly, this C3aR network includes multiple genes linked to late-onset AD. 30415998 2018
CUI: C0338656
Disease: Impaired cognition
Impaired cognition
0.020 Biomarker disease BEFREE Here we show that the expression of C3 and C3a receptor (C3aR1) are positively correlated with cognitive decline and Braak staging in human AD brains. 30415998 2018
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease
0.020 Biomarker disease BEFREE We found a strong positive correlation of platelet complement C3aR expression with activated glycoprotein IIb/IIIa in patients with coronary artery disease and coexpression of C3aR with glycoprotein IIb/IIIa in thrombi obtained from patients with myocardial infarction. 29802205 2018
CUI: C0028754
Disease: Obesity
Obesity
0.020 Biomarker disease BEFREE The neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis. 28123945 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.020 Biomarker disease BEFREE Here we report that astrocytic complement activation also regulates Aβ dynamics in vitro and amyloid pathology in AD mouse models through microglial C3aR. 26758846 2016
CUI: C0036690
Disease: Septicemia
Septicemia
0.020 Biomarker disease BEFREE Our results highlight a novel role for complement and the Cpb1-C3-C3aR pathway in proinflammatory signaling, caspase-11 cell death, and sepsis severity. 27697835 2016
CUI: C0243026
Disease: Sepsis
Sepsis
0.020 Biomarker disease BEFREE Our results highlight a novel role for complement and the Cpb1-C3-C3aR pathway in proinflammatory signaling, caspase-11 cell death, and sepsis severity. 27697835 2016